REFERENCES
- BuBose TD, Jr. American Society of Nephrology Presidential Address 2006: Chronic kidney disease as a public health threat: New strategy for a growing problem. J Am Soc Nephrol. 2007; 18: 1038–1045
- Futrakul N, Vongthavarawat V, Sirisalipotch S, Chaiwatanarat P, Futrakul P, Suwanwalaikorn S. Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes. Clin Hemorheol Microcirc. 2005; 32: 59–65
- Lewis EJ, Hunsicker LG, Clarke WR, Bul T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rhode R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesarten in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851–860
- Mogensen CE, Neldam S, Tikkanen I, Uren S, Viskoper R, Watts RE, Cooper ME. Randomized controlled trial of dual blockage of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000; 321: 1440–1443
- Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Anduson S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870–878
- Rossing K, Jasobsan P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 26: 268–274
- Futrakul N, Butthep P, Futrakul P, Sitprija V. Improvement of renal function in type 2 diabetic nephropathy. Ren Fail. 2007; 29: 155–158
- Futrakul P, Yenrudi S, Futrakul N, Sensirivatana R, Kingwatanakul P, Jungthirapanich J, Cherdkiadtikul T, Laohapaibul A, Watana D, Singkhusa V, Futrakul S, Pongsin P. Tubular function and tubulointerstitial disease. Am J Kidney Dis. 1999; 33: 886–891
- Forstermann U, Munzel T. Endothelial nitric oxide synthese in vascular disease from marvel to menace. Circulation. 2006; 113: 1708–1714
- Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation. 2003; 107: 1308–1314
- Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder JD, Tsikas D, Erlt G, Bauersachs J. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007; 56: 666–674
- Lindenmeyer MT, Kretzler M, Boucherot A, Berrn S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MS, Schrier RW, Schlondorff D, Cohen CD. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007; 18: 1765–1776
- Nakagawa T, Sato W, Suertin YY, Glushakova D, Croker B, Atkinson MA, Tisher CC, Johnson RJ. Uncoupling of a vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol. 2006; 17: 736–745
- Fiedler U, Reiss Y, Scharfenecker M, Grunow V, Koidl S, Thurston G. Angiopoietin-1 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006; 12: 235–239